User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

5877

Interactions with Platform & by Email *

INTERACTIONS

940

Unique # Participated *

PARTICIPANTS

176

Responses Validated *

VALIDATIONS

38

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Current and Future Market Analysis.....II-1
Analysis by Geographic Region.....II-1
Analysis by Formulation.....II-1
Key Market Drivers.....II-1
Market Inhibitors.....II-1
1$100
   Market Characterized by Large Untreated Patient Pool.....II-2
Market Competition.....II-2
Number of Anemia Drugs by Development Phase.....II-2
Table 1: Number of Anemia Drugs under Different Development Phases, Including Marketed Drugs (2009) (includes corresponding Graph/Chart).....II-2
1$350
   Major Companies in Early-Stage Anemia Drugs.....II-3
Table 2: List of Major 5 Early-Stage Companies (Preclinical or Phase I) Along with the Number of Anemia Products Offered (2009).....II-3
Existing Drugs for Treatment of Anemia.....II-3
List of Existing Anemia Drugs Available in the Market, along with Indication
  (2009).....II-3
1$350
   Pipeline Drugs.....II-4
List of Select Pipeline Drugs for Treatment of Anemia (2009).....II-4
Patent Expiry for Major Anemia Drugs.....II-4
Major Anemia Drugs Available in the US Market Along with their Patent Expiry
  Year.....II-4
1$100
   Introduction to ESAs.....II-5
Short-acting ESAs.....II-5
Long-acting ESAs.....II-5
Global Market Overview.....II-5
1$100
   Market Restraints.....II-6
Dosage Frequency.....II-6
Risk of Cardiovascular Events and PRCA.....II-6
Lack of Effectiveness.....II-6
Lack of Product Differentiation.....II-6
1$100
   Lack of Cost-Effectiveness for Health Insurance Providers.....II-7
Changing Dynamics of Use of ESAs Worldwide.....II-7
Latent Decline in Use of ESAs to Spur IV Iron Market.....II-7
1$100
   Aranesp® (Darbepoetin alfa).....II-8
Contraindications of Aranesp®.....II-8
Side Effects Profile.....II-8
EPOGEN® (Epoetin alfa).....II-8
1$100
   Contraindications of Epogen.....II-9
Side Effects Profile.....II-9
PROCRIT (Epoetin alfa).....II-9
1$100
   Contraindications of PROCRIT.....II-10
Side Effects Profile.....II-10
MIRCERA.....II-10
Contraindications of MIRCERA.....II-10
Side Effects Profile.....II-10
A Quick Insight into Select Promising Pipeline Candidates.....II-10
FG-2216 (FibroGen and Astellas).....II-10
1$100
   PBI-1402 (ProMetic).....II-11
Hematide (Affymax and Takeda).....II-11
1$100
   AKB-6548 (Akebia).....II-12
ACE-536 (Acceleron).....II-12
ACE-011 (Acceleron).....II-12
1$100
   What is Anemia?.....II-13
The Role Of RBCs in Anemia.....II-13
1$100
   Table 3: World Health Organization Recommended Hemoglobin (Hb) Threshold Limit for Anemia in g/dl and mmol/l by Age Group for Children, Women and Men (includes corresponding Graph/Chart).....II-14
Classification Approaches.....II-14
Kinetic Approach.....II-14
1$350
   Morphological Approach.....II-15
Risk Factors for Anemia.....II-15
Symptoms of Anemia.....II-15
Possible Complications.....II-15
1$100
   Diagnoses of Anemia.....II-16
Laboratory Tests for Anemia Diagnoses.....II-16
1$100
   Types of Anemia.....II-17
Iron Deficiency Anemia.....II-17
1$100
   Macrocytic Anemia.....II-18
Normocytic Anemia.....II-18
Dimorphic Anemia.....II-18
Heinz Body Anemia.....II-18
Folic Acid Deficiency Anemia.....II-18
1$100
   Vitamin B12 Deficiency Anemia.....II-19
Vitamin C Deficiency Anemia.....II-19
Hemolytic Anemia.....II-19
Autoimmune Hemolytic Anemia.....II-19
1$100
   Sickle Cell Anemia.....II-20
Aplastic Anemia.....II-20
Fanconi Anemia.....II-20
Pregnancy Anemia.....II-20
Anemia of Chronic Disease.....II-20
1$100
   Disease-induced/ Treatment-induced Anemia.....II-21
Anemia Associated with CKD.....II-21
Anemia Associated with ESRD.....II-21
1$100
   Anemia Associated with Cancer.....II-22
Chemotherapy-induced Anemia.....II-22
Anemia Associated with Other Conditions.....II-22
Treatment of Anemia.....II-22
1$100
   Erythropoiesis-Stimulating Agents (ESAs).....II-23
Blood Transfusion.....II-23
1$100
   Hyperbaric Oxygen Treatment.....II-24
Supplements Treatment.....II-24
Iron Supplements/Therapy.....II-24
1$100
   Folic Acid Supplements.....II-25
Vitamin B12 Supplements.....II-25
Nutritional Treatment.....II-25
Herbal Treatment.....II-25
1$100
   Homeopathy Treatment.....II-26
Alternative Treatment.....II-26
1$100
   Affymax Concludes Patient Treatment in Phase III Program for Hematide™.....II-27
Akebia Announces Results from Phase 1a Clinical Trial on AKB-6548.....II-27
Acceleron Releases Data from Animal Studies on ACE-536.....II-27
1$100
   Genzyme Corp. Releases Phase III Clinical Trial Data of FluCAM.....II-28
Palkion Initiates Preclinical Study for Oral Anemia Drug.....II-28
1$100
   AMAG Pharmaceuticals Introduces Feraheme™ Injection.....II-29
Acceleron Pharma and Celgene Commence Phase II Clinical Trial of ACE-011.....II-29
FibroGen Enters into Phase-II Clinical Trials for FG-4592/ASP1517.....II-29
FibroGen Resumes Patient Enrollment Process for Phase II Trial of
  FG-4592/ASP1517.....II-29
1$100
   HemaQuest Pharmaceuticals Completes Phase I Clinical Trial of HQK-1001.....II-30
Astellas Obtains Clearance to Resume Clinical Trials of YM 311.....II-30
Takeda and Affymax Suspends Clinical Trials of Hematide™ in Chemotherapy-Induced
  Anemia.....II-30
St. John Hospital and Medical Center Completes Phase-III Clinical Trials for
  Ferumoxytol.....II-30
1$100
   ProMetic Life Sciences Releases Phase II Clinical Trial Data of Oral PBI-1402.....II-31
Health Canada Issues Notice of Compliance to Roche for MIRCERA.....II-31
Sandoz Obtains EC Approval for Biosimilar Epoetin Alfa.....II-31
Hospira Obtains EC Clearance for Retacrit™.....II-31
1$100
   Roche Obtains EC Approval for Mircera in Anemia Treatment.....II-32
Roche Launches Mircera in Germany and UK.....II-32
Roche Secures European Approval for NeoRecormon.....II-32
Neose Obtains FDA Clearance for Clinical Trials on NE-180.....II-32
1$100
   Affymax Receives Milestone Payment from Takeda for Hematide.....II-33
AMAG and Takeda Ink Licensing Deal.....II-33
District Court Prevents Launch of Roche’s Mircera in US.....II-33
Chugai Files for Approval of Epogin® for Additional Indication in Japan.....II-33
1$100
   Watson Pharmaceuticals and GeneraMedix Ink Licensing Agreement.....II-34
Chugai Files for Approval of R744 for Renal Anemia in Japan.....II-34
OPK Biotech Expands Production and Research Activities.....II-34
GSK and Entelos Team Up for Silico Research in Developing Novel Anti-Anemia
  Drugs.....II-34
1$100
   Clinical Data Acquires Adenosine Therapeutics.....II-35
StemCyte Inks JV Agreement with Cadila and Apollo Hospitals.....II-35
Prolong Pharmaceuticals and Zydus Cadila Enters into Collaboration.....II-35
1$100
   ProQuest Investments Enters into Joint Venture with CrystalGenomics.....II-36
FDA Accepts IND for Icagen’s Senicapoc.....II-36
1$100
   Acceleron Pharma, Inc. (US).....II-37
Akebia Therapeutics, Inc. (US).....II-37
Amgen, Inc. (US).....II-37
1$100
   Bristol-Myers Squibb Company (US).....II-38
Centocor Ortho Biotech Products, L.P. (US).....II-38
1$100
   F. Hoffmann-La Roche Ltd. (Switzerland).....II-39
Chugai Pharmaceutical Co. Ltd. (Japan).....II-39
Fibrogen, Inc. (US).....II-39
1$100
   GlaxoSmithKline PLC (UK).....II-40
Hospira, Inc. (US).....II-40
Novartis International AG (Switzerland).....II-40
1$100
   Pfizer, Inc. (US).....II-41
ProMetic Life Sciences, Inc. (Canada).....II-41
1$100
   Takeda Pharmaceutical Company Limited (Japan).....II-421$100
   Analytics By Geographic Region.....II-43
Table 4: World Recent Past, Current and Future Analysis for Anemia Drugs by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-43
1$350
   Table 5: World Historic Review for Anemia Drugs by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-441$350
   Table 6: World 15-Year Perspective for Anemia Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2003, 2009 and 2015 (includes corresponding Graph/Chart).....II-451$350
   Analytics By Drug Formulation.....II-46
Table 7: World Recent Past, Current & Future Market Analysis for Anemia Drugs by Formulation - Short Acting ESAs and Long Acting ESAs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-46
1$350
   Table 8: World Historic Review Markets for Anemia Drugs by Formulation - Short Acting ESAs and Long Acting ESAs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-471$350
   Table 9: World 15-Year Perspective for Anemia Drugs by Formulation - Percentage Breakdown of Dollar Sales for Short Acting ESAs and Long Acting ESAs for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart).....II-481$350
   A. Market Analysis.....III-1
Outlook.....III-1
FDA Amendments Prune Anemia Market for ESA Therapies.....III-1
1$75
   High Unmet Healthcare Needs and Challenges Abound in CKD Non-Dialysis Sector.....III-2
Growing Need for Iron Replacement Anemia Drugs.....III-2
Vifor's Venofer – The Leading Iron-Replacement Drug.....III-2
1$75
   Product Approvals and Clinical Trials.....III-34$150
   Strategic Corporate Developments.....III-72$100
   Select Players.....III-94$150
   B. Market Analytics.....III-13
Table 10: US Recent Past, Current and Future Analysis for Anemia Drugs by Formulation - Short Acting ESAs and Long Acting ESAs Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-13
1$200
   Table 11: US Historic Review for Anemia Drugs by Formulation - Short Acting ESAs and Long Acting ESAs Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-141$200
   Table 12: US 13-Year Perspective for Anemia Drugs by Formulation - Percentage Share Breakdown of Dollar Sales for Short Acting ESAs and Long Acting ESAs for Years 2003, 2009 and 2015 (includes corresponding Graph/Chart).....III-151$200
   A. Market Analysis.....III-16
Current & Future Analysis.....III-16
European Approval of Biosimilars of Anemia Drugs.....III-16
European Approved Anemia Drugs.....III-16
1$75
   Product Approvals and Clinical Trials.....III-171$75
   Select Players.....III-182$100
   B. Market Analytics.....III-20
Table 13: European Recent Past, Current and Future Analysis for Anemia Drugs with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-20
1$200
   Table 14: European Historic Review for Anemia Drugs with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-211$200
   A. Market Analysis.....III-22
Outlook.....III-22
Product Approvals and Clinical Trials.....III-22
1$75
   Strategic Corporate Developments.....III-231$75
   Select Players.....III-242$100
   B. Market Analytics.....III-26
Table 15: Rest of World Recent Past, Current and Future Analysis for Anemia Drugs with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-26
1$200
   Table 16: Rest of World Historic Review for Anemia Drugs with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-271$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com